Is there any domestically produced medicine for Gefitinib?

Gefitinib (Gefitinib) is a drug used to treat non-small cell lung cancer (NSCLC) and belongs to the tyrosine kinase inhibitor (TKI) class of drugs. It inhibits the growth and spread of tumor cells by inhibiting the activity of epidermal growth factor receptor (EGFR) tyrosine kinase in tumor cells. Gefitinib is a targeted therapy drug mainly used for patients with non-small cell lung cancer who carry EGFR gene mutations.

Gefitinib was launched in China in 2005. At that time, the price of a box was about 5,000 yuan. In 2017 it entered the domestic medical insurance. After the medical insurance, the price dropped a lot. There are domestically produced drugs in the country. Please consult the local hospital pharmacy or the medical insurance bureau for the specific price after the medical insurance. Other versions include original drugs and cost-effective generic drugs. The generic drugs include generic drugs from India, Bangladesh and Laos. The prices vary with different specifications, about 200~800 yuan, and the ingredients of generic drugs are basically the same as domestic drugs.

Gefitinib acts on the cell surfaceEGFR, a receptor tyrosine kinase that plays a key role in cell growth and division. EGFR mutations or overexpression are associated with the occurrence and progression of some non-small cell lung cancers. Gefitinib inhibits the tyrosine kinase activity of EGFR, thereby interfering with the signaling pathways of cancer cells and preventing the growth and spread of cancer cells.

Gefitinib is mainly used to treat advanced or metastatic non-small cell lung cancer carrying EGFR mutations. EGFRmutations are one of the most common mutations in lung cancer, and these mutations can cause cancer cells to overgrow. Gefitinib can significantly improve the condition and delay disease progression in these patients.